OneSpan (NASDAQ:OSPN) Azioni

OneSpan

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.

OneSpan Inc

NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Scorpius Holdings, Inc. (the "Company") — ticker symbol SCPX — from NYSE American. Trading in the Company's common stock will be suspended immediately.
NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company's common stock.
The Company has a right to a review of the staff's determination to delist the Company's common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the Company's common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

News

SCPX

NYSE American To Commence Delisting Proceedings Against Scorpius Holdings, Inc.

Management

AEON

AEON Biopharma Appoints Rob Bancroft As President And Chief Executive Officer, Effective April 29, 2025

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) reported quarterly earnings of $1.86 per share which missed the analyst consensus estimate of $2.00 by 7 percent. This is a 2.62 percent decrease over earnings of $1.91 per share from the same period last year.

Earnings

Earnings Misses

BOKF

BOK Financial Q1 EPS $1.86 Misses $2.00 Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54240820&amp;newsitemid=20250420178680&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=bcb97a0a3c8892614f1297db580584e5">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) Program <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseer.cancer.gov%2Fdata%2Fspecialized%2Favailable-databases%2Fdecipher-prostate-gc-request%2F&amp;esheet=54240820&amp;newsitemid=20250420178680&amp;lan=en-US&amp;anchor=just+released&amp;index=2&amp;md5=85917c7b4d1ecea2f5d8dfbbb5a0ff09">just released</a>. This database will enable eligible researchers to evaluate Decipher Prostate test results in the context of real-world patient outcomes, prostate cancer characteristics, treatment protocols, demographics and other factors.
 &nbsp;

VCYT

Veracyte Says Data From Decipher Prostate Genomic Classifier Are Linked to Real-World Data in NCI's SEER Specialized Database Release

Metropolitan Bank Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCB#NYSE">MCB</a>) reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.35 by 7.41 percent. This is a 0.68 percent decrease over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $70.590 million which beat the analyst consensus estimate of $67.626 million by 4.38 percent. This is a 5.81 percent increase over sales of $66.713 million the same period last year.

Earnings Beats

Metropolitan Bank Holding Q1 2025 GAAP EPS $1.45 Beats $1.35 Estimate, Sales $70.590M Beat $67.626M Estimate

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MSbrdBsxJ0qK1Hj5j32O9kSuaaIEPlFy7PmtIxywiqqk-HPG63iZ18NRE68gahrcwR8IxrDuxFrLIitrFhXrGbD9WKdetDrUMBGMYHQM9_U=">Myriad Genetics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a <a href="https://www.globenewswire.com/Tracker?data=EVbdMn8J2O5vDqy9XKemwDnKWY8ibd26P1rodSxpoEe9EWW2WGtweVF3EV9dgVhX4Oq6dnoddPY_isYVst4Gl2FKQiEWskHCUAd1lHqBuo_rZ7j8CjyLYZHU-R_7QEmiYRZGkxNwACJ6cEH3TUxJAwFUEuEFbpd-Blm35t_dXbzee7er-FNleB_elq4rxm3sqvjUX-LWUdYM7TPlTviNUw==">study</a> showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the <a href="https://www.globenewswire.com/Tracker?data=PfxZJVr4wc8HUvRb9IBcvYvJgAw8uqyk1tq6nkURzvry5u4pdhG62_gnKxXfX7I4RS6dqH7ZQ2NSIk_NquRfFw==">GeneSight</a>&#xAE; Psychotropic Test.
"Millions of Americans face major depressive disorder each year, and the GeneSight test provides genetic insights that may help healthcare providers personalize the selection of mental health medications," said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. "This study found lower psychiatric-related hospitalizations following use of the GeneSight test, suggesting that GeneSight may help healthcare providers identify effective medications and reduce the trial-and-error prescribing process that can lead to increased healthcare resource utilization."
The publication includes additional analysis of the study results first&nbsp;<a href="https://www.globenewswire.com/Tracker?data=aawoQwA-i27wRPhv0IckRGvSsR97UwileLPHExF26qW015wldfgv0mxsK05eC7fx6CMt58v0EoB97rF_nlp5qIu2P65PNdDGuc6Q1UIE93qyFFWalQEZl1o3SPkM8oIFn4CsVaHKr2dJ1POVGYFKpA==">shared</a> at the 2024 American Association of Psychiatric Pharmacists conference. The study, entitled "Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients with Major Depressive Disorder," showed, following GeneSight testing:
<ul>
<li>There was an almost 40% relative reduction in the proportion of patients who filled prescriptions with significant gene-drug interactions. We believe these data suggest that healthcare providers are using the GeneSight test to inform treatment decisions.</li>
<li>A 39% relative reduction in psychiatric-related hospitalizations and a 29% relative reduction in hospitalizations for any reason were observed.</li>
<li>Patients who were switched to medications with no/moderate gene-drug interactions had a 44% relative reduction in psychiatric hospitalizations and a 34% relative reduction in hospitalizations for any reason. &nbsp;</li>
</ul>
"As a practicing psychiatrist, this study reinforces my decision to order the GeneSight test for my patients. Many patients don't respond well to the first prescribed medication and the rate of positive medication response declines after that1," said Dr. Crystal Nelson, a psychiatrist in Newnan, GA. "My patients who suffer from major depressive disorder often share a renewed sense of hope after I tell them about and order the GeneSight test. Many of them share that they are relieved to learn that genetics may have been a reason why a medication failed them."
_______________ 1 American Journal of Psychiatry. "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR&#x2A;D report" <a href="https://www.globenewswire.com/Tracker?data=RgRQa9K9caAn3yx1f0CpDJ-mVM1CWZkP24POoIhuIJoCv77GBMX0cASQPmbRoS9pvHJq1FXz-lWstgigaHbrhYUs27HC6eogmlDS_OM7Z4n1W1aKlU6gnoFUULUmpfHtq1HYLWE5FplAwUnzrtiDVQ==">https://pubmed.ncbi.nlm.nih.gov/17074942/</a> &nbsp;
About the Study The study analyzed a dataset generated by linking more than a half million de-identified patients who received the GeneSight test to administrative insurance claims from a nationwide data warehouse in the United States. Nearly 21,000 patients with major depressive disorder met inclusion criteria to be included in the study. The study authors then evaluated this dataset with regard to medications prescribed before and after GeneSight testing, as well as healthcare resource utilization before and after GeneSight testing. The company believes that GeneSight testing contributed to the reduction in patients who filled prescriptions with significant gene-drug interactions and the reduction in hospitalizations, but the study did not include an analysis of a non-GeneSight control group to evaluate whether or to what extent GeneSight testing was the cause of these reductions.

Biotech

General

MYGN

Myriad Genetics Releases Study Results That Shows Patients With Depression Had Fewer Psychiatric Hospitalizations After GeneSight Testing

APPN

Appian Appoints Serge Tanjga As CFO, Effective May 27

Servisfirst Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NYSE">SFBS</a>) reported quarterly earnings of $1.16 per share which missed the analyst consensus estimate of $1.18 by 1.69 percent. This is a 23.4 percent increase over earnings of $0.94 per share from the same period last year.

SFBS

Servisfirst Bancshares Q1 Adj $1.16 Misses $1.18 Estimate

XAIR

Beyond Air's NeuroNOS Subsidiary Receives FDA Orphan Drug Designation For Phelan-McDermid Syndrome

CSWC

Capital Southwest Corporation Subsidiary Receives US Small Business Administration License To Operate Small Business Investment Company

JP Morgan analyst Arun Jayaram trimmed the price forecast for Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) following first-quarter<a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener"> results reported last week</a>.
Liberty Energy reported quarterly earnings of 4 cents per share, which missed the analyst consensus estimate of 5 cents per share, and sales of $977.46 million, which beat the analyst <a target="_blank" href="https://www.benzinga.com/25/04/44858147/why-liberty-energy-shares-are-trading-higher-by-9-here-are-20-stocks-moving-premarket" rel="noreferrer noopener">consensus estimate of $954.73 million</a>.
The company notes that a temporary pause in tariffs has eased economic pressure and reduced<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44853604/liberty-energy-inc-announces-first-quarter-2025-financial-and-operational-results" rel="noreferrer noopener"> immediate concerns about oil demand</a>.
Nonetheless, the management notes that the attention remains on supply factors, including shifts in OPEC+ strategy and potential export constraints from Iran, Russia, and Venezuela.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44564627/liberty-energy-1q-earnings-preview-and-key-takeaways-from-meeting-management-team" rel="noreferrer noopener">Liberty Energy 1Q Earnings Preview And Key Takeaways From Meeting Management Team</a>
While commodity price volatility hasn&#8217;t yet shifted North American production plans, management expects oil producers<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> to assess potential impacts on pricing</a>.
Jayaram slashed the price forecast from $18 to $16 <a target="_blank" href="https://www.benzinga.com/quote/LBRT/analyst-ratings" rel="noreferrer noopener">while reiterating a Neutral rating</a>.
The analyst says that the company&#8217;s outlook reflects strong momentum from the first quarter to continue into the second quarter of FY25.
Activity levels are likely to remain stable for Publics and larger operators, which make up LBRT's primary customer base, adds the analyst.
Nevertheless, Jayaram writes that there may be emerging risks to activity in the second half of 2025.
The analyst slightly lowered the second-quarter EBITDA estimates to $173 million (up 2.9% quarter-over-quarter) from the previous estimate of $175 million.
The revision brings the estimate just below the mid-single-digit sequential EBITDA growth that management indicated during the earnings call, the analyst adds.
Also, Jayaram lowered the 2025/2026 EBITDA estimates to $680 million/$703 million (from $702 million/$839 million previously), and FCF generation estimates to $72 million/$26 million (from $31 million/$88 million earlier).
Price Action: LBRT shares were down 4.4% at $11.54 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44793519/energy-secretary-chris-wright-is-bullish-as-oil-prices-crater" target="_blank" rel="noreferrer noopener">Energy Secretary Chris Wright Is &#8216;Bullish&#8217; As Oil Prices Crater</a></li>
</ul>
Photo: katjen/Shutterstock

Equities

Price Target

Small Cap

Movers

LBRT

Liberty Energy's Momentum Carries Into Q2 As JPMorgan Tracks Growing Supply-Side Risks

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients.
DT-168 is a GeneTAC&#xAE; small molecule, formulated as an eye drop, that is designed to selectively target the CTG repeat expansion in the TCF4 gene and reduce the expression of the mutant gene product that causes corneal endothelial cell dysfunction leading to FECD.

DSGN

Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025

AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.40 by 10 percent. This is a 24.14 percent decrease over earnings of $0.58 per share from the same period last year.

AGNC

AGNC Investment Q1 Adj $0.44 Beats $0.40 Estimate

Trustco Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRST#NASDAQ">TRST</a>) reported quarterly earnings of $0.75 per share. This is a 17.19 percent increase over earnings of $0.64 per share from the same period last year.

TRST

Trustco Bank Q1 EPS $0.75 Up From $0.64 YoY

Community West Bancshare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWBC#NASDAQ">CWBC</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.50 by 12 percent. This is a 41.94 percent increase over earnings of $0.31 per share from the same period last year.

CWBC

Community West Bancshare Q1 EPS $0.44 Misses $0.50 Estimate

Throughout the last three months, 5 analysts have evaluated ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for ResMed, presenting an average target of $267.0, a high estimate of $286.00, and a low estimate of $240.00. This current average reflects an increase of 1.29% from the previous average price target of $263.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1745265679_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of ResMed by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tim Rezvan &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $269.00&#x7C;$280.00 &#x7C; 
&#x7C;Jonathan Block &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $240.00&#x7C;$250.00 &#x7C; 
&#x7C;David Low &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $286.00&#x7C;$270.00 &#x7C; 
&#x7C;Brett Fishbin &#x7C;Keybanc &#x7C;Raises &#x7C;Overweight &#x7C; $280.00&#x7C;$266.00 &#x7C; 
&#x7C;Adam Maeder &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $260.00&#x7C;$252.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ResMed. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ResMed's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into ResMed's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ResMed analyst ratings.</a>
<h2>Get to Know ResMed Better</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>Key Indicators: ResMed's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, ResMed showcased positive performance, achieving a revenue growth rate of 10.26% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: ResMed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.88% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ResMed's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.6% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.8%, the company showcases effective utilization of assets.
Debt Management: ResMed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing ResMed: Insights From 5 Financial Analysts

Deep-pocketed investors have adopted a bearish approach towards Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in XYZ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Block. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 69% bearish. Among these notable options, 7 are puts, totaling $525,725, and 6 are calls, amounting to $232,744.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $42.5 to $115.0 for Block during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Block's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Block's whale trades within a strike price range from $42.5 to $115.0 in the last 30 days. 
<h3>Block 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745265671_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XYZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.75</td>
<td>$16.6</td>
<td>$16.6</td>
<td>$65.00</td>
<td>$177.6K</td>
<td>1.9K</td>
<td align="right">1</td>
</tr>
<tr>
<td>XYZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$42.50</td>
<td>$125.7K</td>
<td>307</td>
<td align="right">631</td>
</tr>
<tr>
<td>XYZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$8.5</td>
<td>$8.15</td>
<td>$8.2</td>
<td>$65.00</td>
<td>$77.8K</td>
<td>140</td>
<td align="right">100</td>
</tr>
<tr>
<td>XYZ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$42.50</td>
<td>$65.5K</td>
<td>307</td>
<td align="right">219</td>
</tr>
<tr>
<td>XYZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$11.35</td>
<td>$11.2</td>
<td>$11.35</td>
<td>$60.00</td>
<td>$52.2K</td>
<td>54</td>
<td align="right">48</td>
</tr>
</tbody>
</table>

<h3>About Block</h3>
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2024, Square's payment volume was almost USD 250 million.
<h3>Where Is Block Standing Right Now?</h3>
<ul>
<li>With a volume of 4,205,526, the price of XYZ is down -3.21% at $52.17. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 10 days.</li>
</ul>
<h3>What The Experts Say On Block</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $68.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Block, which currently sits at a price target of $80. 
&#x2A; An analyst from Evercore ISI Group has revised its rating downward to In-Line, adjusting the price target to $52. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Block with a target price of $74. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Block with a target price of $70. 
&#x2A; An analyst from Morgan Stanley has elevated its stance to Overweight, setting a new price target at $67. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Block, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

A Closer Look at Block's Options Market Dynamics

Deep-pocketed investors have adopted a bearish approach towards Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COIN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 179 extraordinary options activities for Coinbase Global. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 18% leaning bullish and 36% bearish. Among these notable options, 42 are puts, totaling $3,993,929, and 137 are calls, amounting to $11,648,084.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $2.5 to $500.0 for Coinbase Global during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Coinbase Global options trades today is 1336.19 with a total volume of 50,663.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Coinbase Global's big money trades within a strike price range of $2.5 to $500.0 over the last 30 days.
<h3>Coinbase Global Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745265666_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$20.65</td>
<td>$20.55</td>
<td>$20.65</td>
<td>$140.00</td>
<td>$388.2K</td>
<td>503</td>
<td align="right">261</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$169.5</td>
<td>$166.65</td>
<td>$168.58</td>
<td>$5.00</td>
<td>$303.4K</td>
<td>3.9K</td>
<td align="right">67</td>
</tr>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$48.75</td>
<td>$48.5</td>
<td>$48.63</td>
<td>$220.00</td>
<td>$243.2K</td>
<td>908</td>
<td align="right">148</td>
</tr>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$48.35</td>
<td>$48.0</td>
<td>$48.13</td>
<td>$220.00</td>
<td>$226.2K</td>
<td>908</td>
<td align="right">642</td>
</tr>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$48.7</td>
<td>$47.65</td>
<td>$48.55</td>
<td>$220.00</td>
<td>$194.1K</td>
<td>908</td>
<td align="right">287</td>
</tr>
</tbody>
</table>

<h3>About Coinbase Global</h3>
Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.
After a thorough review of the options trading surrounding Coinbase Global, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Coinbase Global Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,221,221, with COIN's price down by -0.11%, positioned at $174.84.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 17 days.</li>
</ul>
<h3>Expert Opinions on Coinbase Global</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $281.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $245. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Coinbase Global with a target price of $290. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Coinbase Global, targeting a price of $169. 
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Coinbase Global, maintaining a target price of $305. 
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Coinbase Global with a target price of $400. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Coinbase Global options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

COIN

A Closer Look at Coinbase Global's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bullish stance on Freeport-McMoRan.
Looking at options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 34% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $1,276,896 and 19, calls, for a total amount of $1,471,539.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $50.0 for Freeport-McMoRan over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Freeport-McMoRan stands at 2495.91, with a total volume reaching 14,028.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Freeport-McMoRan, situated within the strike price corridor from $28.0 to $50.0, throughout the last 30 days.
<h3>Freeport-McMoRan Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745265661_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$8.0</td>
<td>$7.65</td>
<td>$7.8</td>
<td>$35.00</td>
<td>$482.8K</td>
<td>14.8K</td>
<td>619</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.1</td>
<td>$40.00</td>
<td>$310.1K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.33</td>
<td>$1.18</td>
<td>$1.33</td>
<td>$31.00</td>
<td>$266.0K</td>
<td>6.6K</td>
<td>2.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$3.8</td>
<td>$3.25</td>
<td>$3.8</td>
<td>$37.00</td>
<td>$266.0K</td>
<td>927</td>
<td>0</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$3.4</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$37.00</td>
<td>$215.6K</td>
<td>927</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at the end of December 2024. We expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
Following our analysis of the options activities associated with Freeport-McMoRan, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Freeport-McMoRan</h3>
<ul>
<li>Currently trading with a volume of 7,494,134, the FCX's price is up by 0.15%, now at $32.95. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 3 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freeport-McMoRan</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $43.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Perform rating on Freeport-McMoRan with a target price of $40. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Freeport-McMoRan, which currently sits at a price target of $45. 
&#x2A; Showing optimism, an analyst from Wolfe Research upgrades its rating to Outperform with a revised price target of $39. 
&#x2A; An analyst from Raymond James has decided to maintain their Outperform rating on Freeport-McMoRan, which currently sits at a price target of $51. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Freeport-McMoRan with a target price of $42. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Freeport-McMoRan options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Spotlight on Freeport-McMoRan: Analyzing the Surge in Options Activity

Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.33, with a high estimate of $22.00 and a low estimate of $16.50. A decline of 5.34% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745265657_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of KeyCorp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Konrad &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Outperform &#x7C; $18.00&#x7C;$20.00 &#x7C; 
&#x7C;Jason Goldberg &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $20.00&#x7C;$21.00 &#x7C; 
&#x7C;David George &#x7C;Baird &#x7C;Maintains &#x7C;Outperform &#x7C; $18.00&#x7C;$18.00 &#x7C; 
&#x7C;Vivek Juneja &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $16.50&#x7C;$18.50 &#x7C; 
&#x7C;Mike Mayo &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $20.00&#x7C;$22.00 &#x7C; 
&#x7C;Keith Horowitz &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $19.00&#x7C;$20.00 &#x7C; 
&#x7C;Brian Foran &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $18.00&#x7C;$19.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $20.00&#x7C;$22.00 &#x7C; 
&#x7C;Keith Horowitz &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $20.00&#x7C;- &#x7C; 
&#x7C;Vivek Juneja &#x7C;JP Morgan &#x7C;Announces &#x7C;Neutral &#x7C; $18.50&#x7C;- &#x7C; 
&#x7C;Gerard Cassidy &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $18.00&#x7C;$18.00 &#x7C; 
&#x7C;Terry McEvoy &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $20.00&#x7C;$20.00 &#x7C; 
&#x7C;Peter Winter &#x7C;DA Davidson &#x7C;Lowers &#x7C;Buy &#x7C; $21.00&#x7C;$22.00 &#x7C; 
&#x7C;David Konrad &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Outperform &#x7C; $21.00&#x7C;$22.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $22.00&#x7C;$23.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to KeyCorp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of KeyCorp compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for KeyCorp's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of KeyCorp's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KEY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on KeyCorp analyst ratings.</a>
<h2>Unveiling the Story Behind KeyCorp</h2>
With assets of over $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
<h3>Financial Insights: KeyCorp</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, KeyCorp showcased positive performance, achieving a revenue growth rate of 117.4% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: KeyCorp's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.4%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): KeyCorp's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.29%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: KeyCorp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.89.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

OneSpan

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO